The DESTINY-Breast09 trial compared continuous TDXD+pertuzumab against THP, which was largely treated as a short induction followed by maintenance. This design difference—continuous therapy versus induction/maintenance—may contribute to the superior outcomes seen with the TDXD arm, making it a slightly uneven comparison.

Data from DESTINY-Breast09 shows TDXD plus pertuzumab dramatically improved progression-free survival in first-line metastatic HER2+ breast cancer. This unprecedented efficacy raises new questions about optimal treatment duration and the potential for de-escalated maintenance therapy after induction.

Positive data from both DESTINY-Breast09 (TDXD-based) and PATINA (CDK4/6i maintenance) create a new dilemma. With similar PFS outcomes, the first-line choice for metastatic HER2+/HR+ patients now hinges on toxicity profiles and patient preference rather than a single efficacy winner.

The global patient population in the pivotal DESTINY-Breast09 trial had less prior exposure to modern agents like pertuzumab and T-DM1 than is typical in Western clinics. This context is crucial when applying the trial's results to more heavily pre-treated populations.

The DESTINY-Breast11 trial showed a neoadjuvant regimen of TDXD followed by THP achieved a 67.3% pathologic complete response (pCR) rate in high-risk HER2+ breast cancer. This is the highest pCR rate seen in a registrational trial, signaling a potential new standard of care.

A subtle finding in the DESTINY-Breast11 trial, where TDXD alone underperformed TDXD followed by THP, suggests that taxane-based chemotherapy might remain effective even after a patient's HER2-positive cancer becomes resistant to the antibody-drug conjugate TDXD.

In the DB09 trial, the median progression-free survival (40 months) was double the median duration of TDXD treatment (20 months). This discrepancy suggests many patients discontinued the cytotoxic component and effectively entered a maintenance phase, validating the induction-maintenance model even within a continuous therapy trial design.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

A key debate in early HER2+ breast cancer is whether to use TDXD neoadjuvantly (DESTINY-Breast11) or reserve it for post-op residual disease (DESTINY-Breast05). Many experts favor the neoadjuvant approach to maximize the chance of a pathologic complete response (pCR), which allows for surgical de-escalation and is associated with better outcomes.